Evidence map›Paper›PMID 38900212›Full record

ArticleBreast cancer research and treatment2024

p53 protein expression patterns associated with TP53 mutations in breast carcinoma.

Sarah A Anderson, Brooke B Bartow, Shuko Harada, Gene P Siegal, Shi Wei, Valeria L Dal Zotto, Xiao Huang

Abstract read
In one paragraph

Article in Breast cancer research and treatment, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Is p53 Immunohistochemistry a Reliable Indicator ofPakistan journal of medical sciences · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. CDK4/6 Inhibitors in Breast Cancer-Who Should Receive Them?International journal of molecular sciences · 2025
    Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sarah A AndersonDepartment of Pathology, The University of Alabama at Birmingham, 619 19th Street South, Birmingham, AL, 35294, USA.
Brooke B BartowDepartment of Pathology, The University of Alabama at Birmingham, 619 19th Street South, Birmingham, AL, 35294, USA.
Shuko HaradaDepartment of Pathology, The University of Alabama at Birmingham, 619 19th Street South, Birmingham, AL, 35294, USA.
Gene P SiegalDepartment of Pathology, The University of Alabama at Birmingham, 619 19th Street South, Birmingham, AL, 35294, USA.
Shi WeiDepartment of Pathology, The University of Alabama at Birmingham, 619 19th Street South, Birmingham, AL, 35294, USA.
Valeria L Dal ZottoDepartment of Pathology, The University of Alabama at Birmingham, 619 19th Street South, Birmingham, AL, 35294, USA.
Xiao HuangDepartment of Pathology, The University of Alabama at Birmingham, 619 19th Street South, Birmingham, AL, 35294, USA. xiaohuang@uabmc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe importance of a TP53 mutation has been demonstrated in several tumor types, including breast cancer (BC). However, the accuracy of p53 protein expression as a predictor of gene mutation has not been well studied in BC. Therefore, we evaluated p53 protein expression associated with TP53 mutations in breast cancers from 64 patients.

methodsTP53 mutation was examined using next-generation sequencing (NGS). p53 protein expression was examined using immunohistochemistry (IHC).

resultsAmong the 64 BCs, 55% demonstrated abnormal expression patterns including 27% overexpression, 22% null, 6% equivocal with 45% having a wild-type pattern. A TP53 mutation was present in 53% (34/64) of tumors including 30% (19/64) demonstrating a missense mutation, 11% (7/64) with a frameshift mutation, 11% (7/64) with a nonsense mutation, and 3% (1/64) with a splice site mutation. Abnormal expression of p53 protein was present in 33 of 34 (97%) tumors carrying a TP53 mutation; conversely, a wild-type pattern was present in 28 of 30 (93%) tumors without a detectable mutation (p < 0.0001). The majority of BCs with a p53 IHC overexpression pattern (15/17, 88%) contained a missense TP53 mutation; while the majority of BCs with a null pattern (12/14, 86%) contained a truncating mutation (p < 0.0001). The BCs with a null pattern are associated with a high Nottingham histological grade and a triple-negative phenotype when compared to those demonstrating overexpression (p < 0.05).

conclusionThese findings suggest that p53 IHC can be a potential surrogate for TP53 mutations in BC. Different p53 expression patterns may correlate with specific TP53 genetic mutations in BC.

Indexed as

Breast NeoplasmsMutationTumor Suppressor Protein p53AdultAgedAged, 80 and overBiomarkers, TumorFemaleHigh-Throughput Nucleotide SequencingHumansImmunohistochemistryMiddle AgedBiomarkers, TumorTP53 protein, humanTumor Suppressor Protein p53Breast carcinomap53 immunohistochemistryTP53 mutation

Identifiers

PMID38900212
PMCPMC11230957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.